| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe
|
Pley, Caitlin
|
|
|
24 |
4 |
p. 343-345
|
artikel
|
| 2 |
Alemnew Dagnew—developing a new TB vaccine
|
Kazi, Farooq
|
|
|
24 |
4 |
p. 348
|
artikel
|
| 3 |
A new global health hub in Germany
|
Samarasekera, Udani
|
|
|
24 |
4 |
p. e226
|
artikel
|
| 4 |
Antibiotic de-escalation: finally, some action and not only words
|
Tabah, Alexis
|
|
|
24 |
4 |
p. 331-333
|
artikel
|
| 5 |
Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis
|
Cong, Bingbing
|
|
|
24 |
4 |
p. 361-374
|
artikel
|
| 6 |
ChatGPT does not neglect a neglected disease, if appropriately prompted – Authors' reply
|
Nacher, Mathieu
|
|
|
24 |
4 |
p. e213
|
artikel
|
| 7 |
Controlling the alarming rise in infectious diseases among children younger than 5 years in Gaza during the war
|
Taha, Amira Mohamed
|
|
|
24 |
4 |
p. e211
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2024; published online Jan 10. https://doi.org/10.1016/S1473-3099(23)00629-1
|
|
|
|
24 |
4 |
p. e221
|
artikel
|
| 9 |
COVAX officially closes
|
Jesudason, Timothy
|
|
|
24 |
4 |
p. e223
|
artikel
|
| 10 |
Dorothy Yeboah-Manu—developing TB expertise in Ghana
|
Kirby, Tony
|
|
|
24 |
4 |
p. 347
|
artikel
|
| 11 |
Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study
|
Cooper, Laura V
|
|
|
24 |
4 |
p. 427-436
|
artikel
|
| 12 |
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
|
López-Cortés, Luis Eduardo
|
|
|
24 |
4 |
p. 375-385
|
artikel
|
| 13 |
Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial
|
Pinazo, Maria-Jesus
|
|
|
24 |
4 |
p. 395-403
|
artikel
|
| 14 |
Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial
|
Bosch-Nicolau, Pau
|
|
|
24 |
4 |
p. 386-394
|
artikel
|
| 15 |
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch
|
Cooper, George
|
|
|
24 |
4 |
p. e209-e210
|
artikel
|
| 16 |
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices
|
Fafi, Inès
|
|
|
24 |
4 |
p. e216-e217
|
artikel
|
| 17 |
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices – Author's reply
|
Li, You
|
|
|
24 |
4 |
p. e218
|
artikel
|
| 18 |
Guinea worm disease inched closer to eradication in 2023
|
Boisson-Walsh, Alix
|
|
|
24 |
4 |
p. e224
|
artikel
|
| 19 |
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
|
Oda, Yoshiaki
|
|
|
24 |
4 |
p. 351-360
|
artikel
|
| 20 |
Infectious diseases surveillance update
|
Zwizwai, Ruth
|
|
|
24 |
4 |
p. e230
|
artikel
|
| 21 |
Inside the circle
|
Prowse, Jamie
|
|
|
24 |
4 |
p. 349
|
artikel
|
| 22 |
Malaria vaccine development in Mali: a step towards transmission-blocking strategies
|
Taha, Amira Mohamed
|
|
|
24 |
4 |
p. e207-e208
|
artikel
|
| 23 |
Mister Stethoscope
|
Bagcchi, Sanjeet
|
|
|
24 |
4 |
p. 350
|
artikel
|
| 24 |
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature
|
Cheok, Kathleen P L
|
|
|
24 |
4 |
p. e256-e265
|
artikel
|
| 25 |
Neal Steigbigel
|
Bagcchi, Sanjeet
|
|
|
24 |
4 |
p. 346
|
artikel
|
| 26 |
New candidate to combat drug-resistant bacteria
|
Bagcchi, Sanjeet
|
|
|
24 |
4 |
p. e227
|
artikel
|
| 27 |
Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital
|
Kotei, Larry
|
|
|
24 |
4 |
p. 337-339
|
artikel
|
| 28 |
Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial
|
Ubals, Maria
|
|
|
24 |
4 |
p. 404-416
|
artikel
|
| 29 |
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2
|
Oda, Yoshiaki
|
|
|
24 |
4 |
p. 341-343
|
artikel
|
| 30 |
Pharmacological innovation and clinical value of VV116
|
Jiang, Mengxi
|
|
|
24 |
4 |
p. e212
|
artikel
|
| 31 |
Renal infarction secondary to Aspergillus spp. embolism following COVID-19
|
de Menezes Neves, Precil Diego Miranda
|
|
|
24 |
4 |
p. e266-e267
|
artikel
|
| 32 |
Repurposing antibiotics to treat syphilis
|
Stafylis, Chrysovalantis
|
|
|
24 |
4 |
p. 335-336
|
artikel
|
| 33 |
Research in brief
|
Devi, Sharmila
|
|
|
24 |
4 |
p. e231
|
artikel
|
| 34 |
Re-visiting humoral constitutive antibacterial heterogeneity in bloodstream infections
|
Abe, Ryuichiro
|
|
|
24 |
4 |
p. e245-e251
|
artikel
|
| 35 |
Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants
|
Herfst, Sander
|
|
|
24 |
4 |
p. 330-331
|
artikel
|
| 36 |
Shifting targets: typhoid's transformation from an environmental to a vaccine-preventable disease, 1940–2019
|
Webster, Emily
|
|
|
24 |
4 |
p. e232-e244
|
artikel
|
| 37 |
Shorter treatment in chronic Chagas disease: a new promise?
|
Bestetti, Reinaldo B
|
|
|
24 |
4 |
p. 333-334
|
artikel
|
| 38 |
Surge of cutaneous leishmaniasis in Pakistan
|
Devi, Sharmila
|
|
|
24 |
4 |
p. e222
|
artikel
|
| 39 |
The oral poliovirus vaccine—a solution and a concern for eradication
|
Faye, Martin
|
|
|
24 |
4 |
p. 336-337
|
artikel
|
| 40 |
The rise of syphilis: a call to action for dermatologists
|
Mehta, Hitaishi
|
|
|
24 |
4 |
p. e219-e220
|
artikel
|
| 41 |
The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting
|
Henaff, Louise
|
|
|
24 |
4 |
p. e214-e215
|
artikel
|
| 42 |
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study
|
Bashorun, Adedapo O
|
|
|
24 |
4 |
p. 417-426
|
artikel
|
| 43 |
Updated criteria for paediatric sepsis and septic shock
|
Venkatesan, Priya
|
|
|
24 |
4 |
p. e225
|
artikel
|
| 44 |
Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines
|
Trkola, Alexandra
|
|
|
24 |
4 |
p. e252-e255
|
artikel
|
| 45 |
Writing and reviewing for us in AI times
|
The Lancet Infectious Diseases,
|
|
|
24 |
4 |
p. 329
|
artikel
|
| 46 |
Zero-Dose Immunization Programme reaches milestone
|
Burki, Talha
|
|
|
24 |
4 |
p. e228-e229
|
artikel
|
| 47 |
Zoonotic tuberculosis in the 21st century
|
Duffy, Shannon C
|
|
|
24 |
4 |
p. 339-341
|
artikel
|
Tijdschrift beschrijving